PARIS, June 28, 2021 /PRNewswire/ -- A new study of Soliqua ® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL, iGlarLixi, met its two primary endpoints and all key ...
After the first 16 patients were treated, the multidisciplinary team met to assess the safety and effectiveness of the insulin infusion protocol. Three changes to the protocol were recommended. The ...
Self-mixing insulin requires a person to inject themselves with two types of insulin in one injection. A person can mix and inject insulin using a syringe. Insulin is a hormone that people use to ...
Offers extended shelf life of 30 days at room temperature or 24 months refrigerated Novel, ready-to-use presentation eliminates need for admixing and batching Available in standardized concentration ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A novel extended-wear insulin infusion ...
Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...
In the last century, advances in the field of insulin therapy have brought us closer to the goal of optimal glycaemic control along with a reduction in diabetes-related complications. However, despite ...
An association between protein catabolism and diabetes has been known for centuries. The Greek physician Aretaeus the Cappadocian described diabetes as a condition that causes “melting of flesh” into ...
Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback